Drug intelligence / Profile preview

palbociclib + anastrozole + letrozole

Development stage: Unknown
Lead developer: Pfizer
Modality: Small Molecules
Administration: Oral

Overview

This is a combination therapy used for hormone receptor-positive (HR+), HER2-negative advanced or metastatic breast cancer. The combination includes palbociclib, a CDK4/6 inhibitor, with aromatase inhibitors (either anastrozole or letrozole). Palbociclib works by preventing cells from transitioning from G1 phase into S phase, while anastrozole and letrozole are aromatase inhibitors that decrease estrogen production in the body. This combination therapy is used to slow tumor growth and prevent cancer from spreading further.

Brand names: Ibrance + Arimidex + Femara

Targets

CDK6 (Cyclin-dependent kinase 6)CDK4 (Cyclin-dependent kinase 4)CYP19A1 (Aromatase)

Beyond the preview

Go deeper on palbociclib + anastrozole + letrozole.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on palbociclib + anastrozole + letrozole.

Explore the full profile